ASP Isotopes Inc. (NASDAQ:ASPI) Short Interest Up 104.3% in January

ASP Isotopes Inc. (NASDAQ:ASPI) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 15,300,000 shares, a growth of 104.3% from the January 15th total of 7,490,000 shares. Approximately 28.2% of the shares of the stock are sold short. Based on an average daily volume of 3,810,000 shares, the short-interest ratio is presently 4.0 days.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group reissued a “buy” rating and issued a $4.50 target price on shares of ASP Isotopes in a report on Friday, October 18th.

Institutional Trading of ASP Isotopes

Large investors have recently bought and sold shares of the company. Hanson & Doremus Investment Management acquired a new stake in shares of ASP Isotopes during the fourth quarter valued at $27,000. Avantax Advisory Services Inc. acquired a new stake in shares of ASP Isotopes during the fourth quarter valued at $45,000. Russell Investments Group Ltd. boosted its stake in shares of ASP Isotopes by 56.3% during the fourth quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company’s stock valued at $46,000 after acquiring an additional 3,682 shares during the last quarter. SVB Wealth LLC purchased a new position in ASP Isotopes during the fourth quarter worth about $49,000. Finally, Boston Financial Mangement LLC purchased a new position in ASP Isotopes during the fourth quarter worth about $50,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

ASP Isotopes Stock Performance

ASP Isotopes stock opened at $5.57 on Thursday. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.55 and a quick ratio of 7.54. ASP Isotopes has a fifty-two week low of $1.86 and a fifty-two week high of $9.33. The stock’s fifty day moving average is $5.22 and its two-hundred day moving average is $4.44.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.